Hepatocellular carcinoma: From diagnosis to treatment

Surgical Oncology

Volumn 25, Issue 2, 2016, Pages 74-85

  Grandhi, Miral Sadaria ^a   Kim, Amy K ^a   Ronnekleiv Kelly, Sean M ^a   Kamel, Ihab R ^a   Ghasebeh, Mounes A ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Ablation; Functional MRI; Hepatocellular carcinoma; Liver transplantation; Sorafenib; Transarterial chemoembolization (TACE)

Indexed keywords

ANTINEOPLASTIC AGENT; IPILUMIMAB; LAMBORLIZUMAB; LENVATINIB; NIVOLUMAB; REGORAFENIB; SORAFENIB; UNCLASSIFIED DRUG;

ABLATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER TRANSPLANTATION; CHEMOEMBOLIZATION; DIAGNOSTIC IMAGING; HISTOLOGY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS;

EID: 84961822808     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2016.03.002     Document Type: Review

References (114)

1. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, and F. Bray Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 Int. J. Cancer 136 2015 E359 E386
2. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
3. K.J. Lafaro, A.N. Demirjian, and T.M. Pawlik Epidemiology of hepatocellular carcinoma Surg. Oncol. Clin. N. Am. 24 2015 1 17
4. G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato Hepatocellular carcinoma in cirrhosis: Incidence and risk factors Gastroenterology 127 2004 S35 S50
5. D. Moradpour, and H.E. Blum Pathogenesis of hepatocellular carcinoma Eur. J. Gastroenterol. Hepatol. 17 2005 477 483
6. M.I. Shariff, I.J. Cox, A.I. Gomaa, S.A. Khan, W. Gedroyc, and S.D. Taylor-Robinson Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics Expert Rev. Gastroenterol. Hepatol. 3 2009 353 367
7. M. Guthle, and M.M. Dollinger Epidemiology and risk factors of hepatocellular carcinoma Radiologe 54 2014 654 659
8. R.J. Wong, R. Cheung, and A. Ahmed Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59 2014 2188 2195
9. J.M. Llovet, C. Bru, and J. Bruix Prognosis of hepatocellular carcinoma: The BCLC staging classification Semin. Liver Dis. 19 1999 329 338
10. A. Duseja Staging of hepatocellular carcinoma J. Clin. Exp. Hepatol. 4 2014 S74 S79
11. J.G. Chen, D.M. Parkin, Q.G. Chen, J.H. Lu, Q.J. Shen, B.C. Zhang, and Y.R. Zhu Screening for liver cancer: Results of a randomised controlled trial in Qidong, China J. Med. Screen 10 2003 204 209
12. A.M. Di Bisceglie, R.K. Sterling, R.T. Chung, J.E. Everhart, J.L. Dienstag, H.L. Bonkovsky, E.C. Wright, G.T. Everson, K.L. Lindsay, A.S. Lok, W.M. Lee, T.R. Morgan, M.G. Ghany, and D.R. Gretch Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial J. Hepatol. 43 2005 434 441
13. O. Soreide, A. Czerniak, H. Bradpiece, S. Bloom, and L. Blumgart Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature Am. J. Surg. 151 1986 518 523
14. D.S. Chen, J.L. Sung, J.C. Sheu, M.Y. Lai, S.W. How, H.C. Hsu, C.S. Lee, and T.C. Wei Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma Gastroenterology 86 1984 1404 1409
15. D. Li, T. Mallory, and S. Satomura AFP-L3: A new generation of tumor marker for hepatocellular carcinoma Clin. Chim. Acta 313 2001 15 19
16. H. Toyoda, T. Kumada, T. Tada, Y. Kaneoka, A. Maeda, F. Kanke, and S. Satomura Clinical utility of highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL Cancer Sci. 102 2011 1025 1031
17. A.S. Lok, R.K. Sterling, J.E. Everhart, E.C. Wright, J.C. Hoefs, A.M. Di Bisceglie, T.R. Morgan, H.Y. Kim, W.M. Lee, H.L. Bonkovsky, and J.L. Dienstag Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma Gastroenterology 138 2010 493 502
18. R. Tateishi, H. Yoshida, Y. Matsuyama, N. Mine, Y. Kondo, and M. Omata Diagnostic accuracy of tumor markers for hepatocellular carcinoma: A systematic review Hepatol. Int. 2 2008 17 30
19. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma J. Hepatol. 56 2012 908 943
20. A. Singal, M.L. Volk, A. Waljee, R. Salgia, P. Higgins, M.A. Rogers, and J.A. Marrero Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis Aliment. Pharmacol. Ther. 30 2009 37 47
21. L. Andreana, G. Isgro, M. Pleguezuelo, G. Germani, and A.K. Burroughs Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis World J. Hepatol. 1 2009 48 61
22. T. Roskams Anatomic pathology of hepatocellular carcinoma: Impact on prognosis and response to therapy Clin. Liver Dis. 15 2011 245 259 vii-x
23. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
24. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: An update Hepatology 53 2011 1020 1022
25. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia Hepatology 49 2009 658 664
26. A. Forner, R. Vilana, C. Ayuso, L. Bianchi, M. Sole, J.R. Ayuso, L. Boix, M. Sala, M. Varela, J.M. Llovet, C. Bru, and J. Bruix Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 2008 97 104
27. A. Villanueva, B. Minguez, A. Forner, M. Reig, and J.M. Llovet Hepatocellular carcinoma: Novel molecular approaches for diagnosis, prognosis, and therapy Annu. Rev. Med. 61 2010 317 328
28. B. Asiyanbola, D. Chang, A.L. Gleisner, H. Nathan, M.A. Choti, R.D. Schulick, and T.M. Pawlik Operative mortality after hepatic resection: Are literature-based rates broadly applicable? J. Gastrointest. Surg. 12 2008 842 851
29. A.J. Page, D.C. Cosgrove, B. Philosophe, and T.M. Pawlik Hepatocellular carcinoma: Diagnosis, management, and prognosis Surg. Oncol. Clin. N. Am. 23 2014 289 311
30. J.M. Llovet, J. Fuster, and J. Bruix Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation Hepatology 30 1999 1434 1440
31. R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, and R. Williams Transection of the oesophagus for bleeding oesophageal varices Br. J. Surg. 60 1973 646 649
32. S.G. Delis, A. Bakoyiannis, C. Dervenis, and N. Tassopoulos Perioperative risk assessment for hepatocellular carcinoma by using the MELD score J. Gastrointest. Surg. 13 2009 2268 2275
33. A. Vitale, T.L. Huo, A. Cucchetti, Y.H. Lee, M. Volk, A.C. Frigo, M. Cescon, F. Tuci, A.D. Pinna, and U. Cillo Survival benefit of liver transplantation versus resection for hepatocellular carcinoma: Impact of MELD score Ann. Surg. Oncol. 22 2015 1901 1907
34. J. Bruix, A. Castells, J. Bosch, F. Feu, J. Fuster, J.C. Garcia-Pagan, J. Visa, C. Bru, and J. Rodes Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure Gastroenterology 111 1996 1018 1022
35. G. Torzilli, M. Makuuchi, K. Inoue, T. Takayama, Y. Sakamoto, Y. Sugawara, K. Kubota, and A. Zucchi No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: Is there a way? A prospective analysis of our approach Arch. Surg. 134 1999 984 992
36. K. Kubota, M. Makuuchi, K. Kusaka, T. Kobayashi, K. Miki, K. Hasegawa, Y. Harihara, and T. Takayama Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors Hepatology 26 1997 1176 1181
37. U. Leung, A.L. Simpson, R.L. Araujo, M. Gonen, C. McAuliffe, M.I. Miga, E.P. Parada, P.J. Allen, M.I. D'Angelica, T.P. Kingham, R.P. DeMatteo, Y. Fong, and W.R. Jarnagin Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure J. Am. Coll. Surg. 219 2014 620 630
38. D. Ribero, E.K. Abdalla, D.C. Madoff, M. Donadon, E.M. Loyer, and J.N. Vauthey Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome Br. J. Surg. 94 2007 1386 1394
39. J.N. Vauthey, G.Y. Lauwers, N.F. Esnaola, K.A. Do, J. Belghiti, N. Mirza, S.A. Curley, L.M. Ellis, J.M. Regimbeau, A. Rashid, K.R. Cleary, and D.M. Nagorney Simplified staging for hepatocellular carcinoma J. Clin. Oncol. 20 2002 1527 1536
40. T.M. Pawlik, K.A. Delman, J.N. Vauthey, D.M. Nagorney, I.O. Ng, I. Ikai, Y. Yamaoka, J. Belghiti, G.Y. Lauwers, R.T. Poon, and E.K. Abdalla Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma Liver Transpl. 11 2005 1086 1092
41. S. Roayaie, K. Obeidat, C. Sposito, L. Mariani, S. Bhoori, A. Pellegrinelli, D. Labow, J.M. Llovet, M. Schwartz, and V. Mazzaferro Resection of hepatocellular cancer
42. B.W. Wang, K.T. Mok, S.I. Liu, N.H. Chou, C.C. Tsai, I.S. Chen, M.H. Yeh, and Y.C. Chen Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma? J. Formos. Med. Assoc. 107 2008 616 626
43. T. Ishizawa, K. Hasegawa, T. Aoki, M. Takahashi, Y. Inoue, K. Sano, H. Imamura, Y. Sugawara, N. Kokudo, and M. Makuuchi Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma Gastroenterology 134 2008 1908 1916
44. M.J. Truty, and J.N. Vauthey Surgical resection of high-risk hepatocellular carcinoma: Patient selection, preoperative considerations, and operative technique Ann. Surg. Oncol. 17 2010 1219 1225
45. S. Arii, S. Tanaka, Y. Mitsunori, N. Nakamura, A. Kudo, N. Noguchi, and T. Irie Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography Oncology 78 Suppl. 1 2010 125 130
46. Y. Nakashima, O. Nakashima, M. Tanaka, K. Okuda, M. Nakashima, and M. Kojiro Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type Hepatol. Res. 26 2003 142 147
47. S. Eguchi, T. Kanematsu, S. Arii, M. Okazaki, K. Okita, M. Omata, I. Ikai, M. Kudo, M. Kojiro, M. Makuuchi, M. Monden, Y. Matsuyama, Y. Nakanuma, K. Takayasu, and Liver Cancer Study Group of J Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey Surgery 143 2008 469 475
48. M. Shi, R.P. Guo, X.J. Lin, Y.Q. Zhang, M.S. Chen, C.Q. Zhang, W.Y. Lau, and J.Q. Li Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: A prospective randomized trial Ann. Surg. 245 2007 36 43
49. R.T. Poon, C. Lau, R. Pang, K.K. Ng, J. Yuen, and S.T. Fan High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: Importance of tumor biomarker in ablative therapies Ann. Surg. Oncol. 14 2007 1835 1845
50. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival Hepatology 37 2003 429 442
51. H. Imamura, Y. Matsuyama, E. Tanaka, T. Ohkubo, K. Hasegawa, S. Miyagawa, Y. Sugawara, M. Minagawa, T. Takayama, S. Kawasaki, and M. Makuuchi Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy J. Hepatol. 38 2003 200 207
52. S. Roayaie, D. Bassi, P. Tarchi, D. Labow, and M. Schwartz Second hepatic resection for recurrent hepatocellular cancer: A Western experience J. Hepatol. 55 2011 346 350
53. V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, F. Bozzetti, F. Montalto, M. Ammatuna, A. Morabito, and L. Gennari Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N. Engl. J. Med. 334 1996 693 699
54. H. Bismuth, P.E. Majno, and R. Adam Liver transplantation for hepatocellular carcinoma Semin. Liver Dis. 19 1999 311 322
55. J. Figueras, E. Jaurrieta, C. Valls, C. Benasco, A. Rafecas, X. Xiol, J. Fabregat, T. Casanovas, J. Torras, C. Baliellas, L. Ibanez, P. Moreno, and L. Casais Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: A comparative study Hepatology 25 1997 1485 1489
56. V. Mazzaferro, J.M. Llovet, R. Miceli, S. Bhoori, M. Schiavo, L. Mariani, T. Camerini, S. Roayaie, M.E. Schwartz, G.L. Grazi, R. Adam, P. Neuhaus, M. Salizzoni, J. Bruix, A. Forner, L. De Carlis, U. Cillo, A.K. Burroughs, R. Troisi, M. Rossi, G.E. Gerunda, J. Lerut, J. Belghiti, I. Boin, J. Gugenheim, F. Rochling, B. Van Hoek, and P. Majno Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis Lancet Oncol. 10 2009 35 43
57. F.Y. Yao, L. Ferrell, N.M. Bass, J.J. Watson, P. Bacchetti, A. Venook, N.L. Ascher, and J.P. Roberts Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival Hepatology 33 2001 1394 1403
58. I.T. Konstantinidis, and Y. Fong Hepatocellular carcinoma in the modern era: Transplantation, ablation, open surgery or minimally invasive surgery? -A multidisciplinary personalized decision Chin. Clin. Oncol. 2 2013 35
59. V. Mazzaferro, S. Bhoori, C. Sposito, M. Bongini, M. Langer, R. Miceli, and L. Mariani Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience Liver Transpl. 17 Suppl. 2 2011 S44 S57
60. S.J. Pelletier, S. Fu, V. Thyagarajan, C. Romero-Marrero, M.J. Batheja, J.D. Punch, J.C. Magee, A.S. Lok, R.J. Fontana, and J.A. Marrero An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data Liver Transpl. 15 2009 859 868
61. F.P. Sarasin, P.E. Majno, J.M. Llovet, J. Bruix, G. Mentha, and A. Hadengue Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective Hepatology 33 2001 1073 1079
62. M. Ninomiya, K. Shirabe, M.E. Facciuto, M.E. Schwartz, S.S. Florman, T. Yoshizumi, N. Harimoto, T. Ikegami, H. Uchiyama, and Y. Maehara Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma J. Am. Coll. Surg. 220 2015 297 304 e293
63. R.S. Rahimi, and J.F. Trotter Liver transplantation for hepatocellular carcinoma: Outcomes and treatment options for recurrence Ann. Gastroenterol. 28 2015 323 330
64. F.Y. Yao, R.K. Kerlan Jr., R. Hirose, T.J. Davern 3rd, N.M. Bass, S. Feng, M. Peters, N. Terrault, C.E. Freise, N.L. Ascher, and J.P. Roberts Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: An intention-to-treat analysis Hepatology 48 2008 819 827
65. S. Shiina, K. Tagawa, T. Unuma, and A. Terano Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma AJR Am. J. Roentgenol. 154 1990 947 951
66. T. Livraghi, A. Giorgio, G. Marin, A. Salmi, I. de Sio, L. Bolondi, M. Pompili, F. Brunello, S. Lazzaroni, G. Torzilli, and et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection Radiology 197 1995 101 108
67. T. Livraghi, L. Bolondi, S. Lazzaroni, G. Marin, A. Morabito, G.L. Rapaccini, A. Salmi, and G. Torzilli Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients Cancer 69 1992 925 929
68. R. Vilana, J. Bruix, C. Bru, C. Ayuso, M. Sole, and J. Rodes Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma Hepatology 16 1992 353 357
69. H. Ishii, S. Okada, H. Nose, T. Okusaka, M. Yoshimori, T. Takayama, T. Kosuge, S. Yamasaki, M. Sakamoto, and S. Hirohashi Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection Cancer 77 1996 1792 1796
70. K.N. Khan, H. Yatsuhashi, K. Yamasaki, M. Yamasaki, O. Inoue, M. Koga, and M. Yano Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection J. Hepatol. 32 2000 269 278
71. T. Livraghi, S.N. Goldberg, S. Lazzaroni, F. Meloni, L. Solbiati, and G.S. Gazelle Small hepatocellular carcinoma: Treatment with radio-frequency ablation oversus enthanol injection Radiology 210 1999 655 661
72. R.A. Lencioni, H.P. Allgaier, D. Cioni, M. Olschewski, P. Deibert, L. Crocetti, H. Frings, J. Laubenberger, I. Zuber, H.E. Blum, and C. Bartolozzi Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection Radiology 228 2003 235 240
73. S.M. Lin, C.J. Lin, C.C. Lin, C.W. Hsu, and Y.C. Chen Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm Gastroenterology 127 2004 1714 1723
74. S. Shiina, T. Teratani, S. Obi, S. Sato, R. Tateishi, T. Fujishima, T. Ishikawa, Y. Koike, H. Yoshida, T. Kawabe, and M. Omata A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma Gastroenterology 129 2005 122 130
75. F. Brunello, A. Veltri, P. Carucci, E. Pagano, G. Ciccone, P. Moretto, P. Sacchetto, G. Gandini, and M. Rizzetto Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial Scand. J. Gastroenterol. 43 2008 727 735
76. S.M. Lin, C.J. Lin, C.C. Lin, C.W. Hsu, and Y.C. Chen Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less Gut 54 2005 1151 1156
77. M.S. Chen, J.Q. Li, Y. Zheng, R.P. Guo, H.H. Liang, Y.Q. Zhang, X.J. Lin, and W.Y. Lau A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma Ann. Surg. 243 2006 321 328
78. M.D. Lu, M. Kuang, L.J. Liang, X.Y. Xie, B.G. Peng, G.J. Liu, D.M. Li, J.M. Lai, and S.Q. Li Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: A randomized clinical trial Zhonghua Yi Xue Za Zhi 86 2006 801 805
79. K. Hasegawa, M. Makuuchi, T. Takayama, N. Kokudo, S. Arii, M. Okazaki, K. Okita, M. Omata, M. Kudo, M. Kojiro, Y. Nakanuma, K. Takayasu, M. Monden, Y. Matsuyama, and I. Ikai Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: A preliminary report of the Japanese nationwide survey J. Hepatol. 49 2008 589 594
80. J. Huang, L. Yan, Z. Cheng, H. Wu, L. Du, J. Wang, Y. Xu, and Y. Zeng A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Ann. Surg. 252 2010 903 912
81. K. Feng, J. Yan, X. Li, F. Xia, K. Ma, S. Wang, P. Bie, and J. Dong A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma J. Hepatol. 57 2012 794 802
82. K. Hasegawa, N. Kokudo, S. Shiina, R. Tateishi, and M. Makuuchi Surgery versus radiofrequency ablation for small hepatocellular carcinoma: Start of a randomized controlled trial (SURF trial) Hepatol. Res. 40 2010 851 852
83. Y. Wang, Q. Luo, Y. Li, S. Deng, S. Wei, and X. Li Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: A meta-analysis of randomized and nonrandomized controlled trials PLoS One 9 2014 e84484
84. D. Li, J. Kang, B.J. Golas, V.W. Yeung, and D.C. Madoff Minimally invasive local therapies for liver cancer Cancer Biol. Med. 11 2014 217 236
85. N.C. Yu, D.S. Lu, S.S. Raman, D.E. Dupuy, C.J. Simon, C. Lassman, B.I. Aswad, D. Ianniti, and R.W. Busuttil Hepatocellular carcinoma: Microwave ablation with multiple straight and loop antenna clusters-pilot comparison with pathologic findings Radiology 239 2006 269 275
86. T. Shibata, Y. Iimuro, Y. Yamamoto, Y. Maetani, F. Ametani, K. Itoh, and J. Konishi Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy Radiology 223 2002 331 337
87. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire N. Engl. J. Med. 332 1995 1256 1261
88. J.M. Llovet, M.I. Real, X. Montana, R. Planas, S. Coll, J. Aponte, C. Ayuso, M. Sala, J. Muchart, R. Sola, J. Rodes, and J. Bruix Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial Lancet 359 2002 1734 1739
89. C.M. Lo, H. Ngan, W.K. Tso, C.L. Liu, C.M. Lam, R.T. Poon, S.T. Fan, and J. Wong Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
90. M. Varela, M.I. Real, M. Burrel, A. Forner, M. Sala, M. Brunet, C. Ayuso, L. Castells, X. Montana, J.M. Llovet, and J. Bruix Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics J. Hepatol. 46 2007 474 481
91. J. Lammer, K. Malagari, T. Vogl, F. Pilleul, A. Denys, A. Watkinson, M. Pitton, G. Sergent, T. Pfammatter, S. Terraz, Y. Benhamou, Y. Avajon, T. Gruenberger, M. Pomoni, H. Langenberger, M. Schuchmann, J. Dumortier, C. Mueller, P. Chevallier, and R. Lencioni Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study Cardiovasc Interv. Radiol. 33 2010 41 52
92. R. Golfieri, E. Giampalma, M. Renzulli, R. Cioni, I. Bargellini, C. Bartolozzi, A.D. Breatta, G. Gandini, R. Nani, D. Gasparini, A. Cucchetti, L. Bolondi, and F. Trevisani Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma Br. J. Cancer 111 2014 255 264
93. S. Gao, Z. Yang, Z. Zheng, J. Yao, M. Deng, H. Xie, S. Zheng, and L. Zhou Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: A meta-analysis Hepatogastroenterology 60 2013 813 820
94. R. Salem, R.J. Lewandowski, M.F. Mulcahy, A. Riaz, R.K. Ryu, S. Ibrahim, B. Atassi, T. Baker, V. Gates, F.H. Miller, K.T. Sato, E. Wang, R. Gupta, A.B. Benson, S.B. Newman, R.A. Omary, M. Abecassis, and L. Kulik Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
95. V. Mazzaferro, C. Sposito, S. Bhoori, R. Romito, C. Chiesa, C. Morosi, M. Maccauro, A. Marchiano, M. Bongini, R. Lanocita, E. Civelli, E. Bombardieri, T. Camerini, and C. Spreafico Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study Hepatology 57 2013 1826 1837
96. B.A. Seinstra, L. Defreyne, B. Lambert, M.G. Lam, H.M. Verkooijen, K.J. van Erpecum, B. van Hoek, A.R. van Erkel, M.J. Coenraad, I. Al Younis, H. van Vlierberghe, and M.A. van den Bosch Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): Study protocol for a randomized controlled trial Trials 13 2012 144
97. S. Bonekamp, Z. Li, J.F. Geschwind, V.G. Halappa, C.P. Corona-Villalobos, D. Reyes, T.M. Pawlik, D. Bonekamp, J. Eng, and I.R. Kamel Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria Radiology 268 2013 420 430
98. C.P. Corona-Villalobos, V.G. Halappa, J.F. Geschwind, S. Bonekamp, D. Reyes, D. Cosgrove, T.M. Pawlik, and I.R. Kamel Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib Eur. Radiol. 25 2015 380 390
99. S. Bonekamp, P. Jolepalem, M. Lazo, M.A. Gulsun, A.P. Kiraly, and I.R. Kamel Hepatocellular carcinoma: Response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data Radiology 260 2011 752 761
100. J.A. Vossen, M. Buijs, and I.R. Kamel Assessment of tumor response on MR imaging after locoregional therapy Tech. Vasc. Interv. Radiol. 9 2006 125 132
101. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, and J. Bruix Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 359 2008 378 390
102. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, J.S. Kim, R. Luo, J. Feng, S. Ye, T.S. Yang, J. Xu, Y. Sun, H. Liang, J. Liu, J. Wang, W.Y. Tak, H. Pan, K. Burock, J. Zou, D. Voliotis, and Z. Guan Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial Lancet Oncol. 10 2009 25 34
103. J. Bruix, T. Takayama, V. Mazzaferro, G.-Y. Chau, J. Yang, M. Kudo, J. Cai, R.T.-P. Poon, K.-H. Han, W.-Y. Tak, H.C. Lee, T. Song, S. Roayaie, L. Bolondi, K.S. Lee, M. Makuuchi, F. Souza, M.-A. Le Berre, G. Meinhardt, and J.M. Llovet STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC) ASCO Annual Meeting Proceedings 2014
104. G.K. Abou-Alfa, P. Johnson, J.J. Knox, M. Capanu, I. Davidenko, J. Lacava, T. Leung, B. Gansukh, and L.B. Saltz Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial Jama 304 2010 2154 2160
105. M. Branda, and J.R. Wands Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma Hepatology 43 2006 891 902
106. M. Kudo Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma World J. Gastroenterol. 18 2012 6005 6017
107. J.M. Llovet, A. Villanueva, A. Lachenmayer, and R.S. Finn Advances in targeted therapies for hepatocellular carcinoma in the genomic era Nat. Rev. Clin. Oncol. 12 2015 436
108. A.L. Cheng, Y.K. Kang, D.Y. Lin, J.W. Park, M. Kudo, S. Qin, H.C. Chung, X. Song, J. Xu, G. Poggi, M. Omata, S. Pitman Lowenthal, S. Lanzalone, L. Yang, M.J. Lechuga, and E. Raymond Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial J. Clin. Oncol. 31 2013 4067 4075
109. C. Cainap, S. Qin, W.T. Huang, I.J. Chung, H. Pan, Y. Cheng, M. Kudo, Y.K. Kang, P.J. Chen, H.C. Toh, V. Gorbunova, F.A. Eskens, J. Qian, M.D. McKee, J.L. Ricker, D.M. Carlson, and S. El-Nowiem Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial J. Clin. Oncol. 33 2015 172 179
110. A.X. Zhu, O. Rosmorduc, T.R. Evans, P.J. Ross, A. Santoro, F.J. Carrilho, J. Bruix, S. Qin, P.J. Thuluvath, J.M. Llovet, M.A. Leberre, M. Jensen, G. Meinhardt, and Y.K. Kang SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma J. Clin. Oncol. 33 2015 559 566
111. P.J. Johnson, S. Qin, J.W. Park, R.T. Poon, J.L. Raoul, P.A. Philip, C.H. Hsu, T.H. Hu, J. Heo, J. Xu, L. Lu, Y. Chao, E. Boucher, K.H. Han, S.W. Paik, J. Robles-Avina, M. Kudo, L. Yan, A. Sobhonslidsuk, D. Komov, T. Decaens, W.Y. Tak, L.B. Jeng, D. Liu, R. Ezzeddine, I. Walters, and A.L. Cheng Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study J. Clin. Oncol. 31 2013 3517 3524
112. J.M. Llovet, T. Decaens, J.L. Raoul, E. Boucher, M. Kudo, C. Chang, Y.K. Kang, E. Assenat, H.Y. Lim, V. Boige, P. Mathurin, L. Fartoux, D.Y. Lin, J. Bruix, R.T. Poon, M. Sherman, J.F. Blanc, R.S. Finn, W.Y. Tak, Y. Chao, R. Ezzeddine, D. Liu, I. Walters, and J.W. Park Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study J. Clin. Oncol. 31 2013 3509 3516
113. A.X. Zhu, M. Kudo, E. Assenat, S. Cattan, Y.K. Kang, H.Y. Lim, R.T. Poon, J.F. Blanc, A. Vogel, C.L. Chen, E. Dorval, M. Peck-Radosavljevic, A. Santoro, B. Daniele, J. Furuse, A. Jappe, K. Perraud, O. Anak, D.B. Sellami, and L.T. Chen Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial Jama 312 2014 57 67
114. A.X. Zhu, J.O. Park, B.Y. Ryoo, C.J. Yen, R. Poon, D. Pastorelli, J.F. Blanc, H.C. Chung, A.D. Baron, T.E. Pfiffer, T. Okusaka, K. Kubackova, J. Trojan, J. Sastre, I. Chau, S.C. Chang, P.B. Abada, L. Yang, J.D. Schwartz, and M. Kudo Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial Lancet Oncol. 16 2015 859 870